Ignite Creation Date:
2025-12-25 @ 3:30 AM
Ignite Modification Date:
2026-01-23 @ 3:52 PM
Study NCT ID:
NCT00193505
Status:
COMPLETED
Last Update Posted:
2011-05-03
First Post:
2005-09-12
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refractory Intermediate Grade B-Cell Lymphoma
Sponsor:
SCRI Development Innovations, LLC
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
SCRI LYM 27
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
None
Responsible Party Affiliation:
Old Name:
John Hainsworth, MD
Old Organization:
Sarah Cannon Research Institute
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | INDUSTRY | View |